Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of QL1012 in Women for Assisted Reproductive Treatment
NCT05149924Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2018
- Primary completion
- Oct 2019
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of QL1012 in female infertility (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Number of oocytes retrieved. Started Oct 2018; status: completed.
02
Drugs
QL1012
03
Conditions
female infertility
Beyond the preview
Go deeper on NCT05149924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05149924.